Denosumab Approval Is “Highly Likely,”– Interview With Amgen’s Perlmutter
Executive Summary
In a Jan. 26 interview, Amgen Executive VP for Research and Development Roger Perlmutter talks about denosumab, follow-on biologics and how Amgen is avoiding the size-related innovation drought that many big pharma companies now face.